Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Other Operating Expenses (2016 - 2021)

Anika Therapeutics (ANIK) has disclosed Other Operating Expenses for 12 consecutive years, with $825000.0 as the latest value for Q4 2021.

  • Quarterly Other Operating Expenses rose 105.27% to $825000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $825000.0 through Sep 2022, up 108.47% year-over-year, with the annual reading at -$21.1 million for FY2021, 8.22% up from the prior year.
  • Other Operating Expenses for Q4 2021 was $825000.0 at Anika Therapeutics, up from -$3.4 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $8.7 million in Q4 2017, with the low at -$24.3 million in Q4 2018.
  • Average Other Operating Expenses over 5 years is $1.0 million, with a median of $5.0 million recorded in 2019.
  • Peak annual rise in Other Operating Expenses hit 30763.64% in 2020, while the deepest fall reached 10200.0% in 2020.
  • Over 5 years, Other Operating Expenses stood at $8.7 million in 2017, then tumbled by 378.56% to -$24.3 million in 2018, then skyrocketed by 99.37% to -$152000.0 in 2019, then tumbled by 10200.0% to -$15.7 million in 2020, then soared by 105.27% to $825000.0 in 2021.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $825000.0, -$3.4 million, and $6.5 million for Q4 2021, Q3 2021, and Q2 2021 respectively.